Neuronetics Q2 2025: Navigating Contradictions in Marketing Strategies and Revenue Expectations
Generated by AI AgentAinvest Earnings Call Digest
Tuesday, Aug 5, 2025 1:05 pm ET1min read
STIM--
Aime Summary
Aime SummaryMarketing strategy and SPRAVATO buy and bill, TMS and SPRAVATO revenue mix at Greenbrook, marketing strategy for traditional STIM business, Greenbrook's contribution to revenue, and revenue growth and seasonality are the key contradictions discussed in Neuronetics' latest 2025Q2 earnings call.
Revenue Growth and Greenbrook Integration:
- NeuroneticsSTIM-- reported total revenue of $38.1 million in Q2 2025, an 18% year-over-year increase on an adjusted pro forma basis.
- Growth was driven by the strength of the Greenbrook clinic business, generating $23 million in revenue, and the integration of Greenbrook operations following the acquisition.
Operational Efficiency and Cash Collections:
- Neuronetics improved cash collections, reducing cash used in operations to $3.5 million, better than the previous target of under $5 million.
- This was achieved through initiatives to address legacy issues with payers, improve claim submission accuracy, and optimize patient flow with self-check-in programs.
SPRAVATO Rollout and Billing Strategy:
- The rollout of SPRAVATO continues with 77 of 83 eligible clinics now offering the therapy.
- The company is taking a more analytical approach to its buy and bill model expansion, focusing on opportunities that deliver good margins based on varying payer reimbursement rates.
Adolescent Growth and Marketing Strategy:
- Neuronetics saw 25% growth in adolescent new patient starts in the first half of 2025 compared to 2024, driven by expanded insurance coverage.
- The company is focusing on educating primary care physicians about the benefits of referring patients for NeuroStar treatment, driven by the Provider Connection Program.
Financial Guidance and Cash Flow Management:
- Neuronetics expects net revenue of $37 million to $39 million for Q3 and targets cash flow from operations to be in the range of negative $3 million to breakeven in Q3, turning positive in Q4.
- This is based on the successful optimization of SPRAVATO buy and bill reimbursements and ongoing operational efficiency improvements.
Revenue Growth and Greenbrook Integration:
- NeuroneticsSTIM-- reported total revenue of $38.1 million in Q2 2025, an 18% year-over-year increase on an adjusted pro forma basis.
- Growth was driven by the strength of the Greenbrook clinic business, generating $23 million in revenue, and the integration of Greenbrook operations following the acquisition.
Operational Efficiency and Cash Collections:
- Neuronetics improved cash collections, reducing cash used in operations to $3.5 million, better than the previous target of under $5 million.
- This was achieved through initiatives to address legacy issues with payers, improve claim submission accuracy, and optimize patient flow with self-check-in programs.
SPRAVATO Rollout and Billing Strategy:
- The rollout of SPRAVATO continues with 77 of 83 eligible clinics now offering the therapy.
- The company is taking a more analytical approach to its buy and bill model expansion, focusing on opportunities that deliver good margins based on varying payer reimbursement rates.
Adolescent Growth and Marketing Strategy:
- Neuronetics saw 25% growth in adolescent new patient starts in the first half of 2025 compared to 2024, driven by expanded insurance coverage.
- The company is focusing on educating primary care physicians about the benefits of referring patients for NeuroStar treatment, driven by the Provider Connection Program.
Financial Guidance and Cash Flow Management:
- Neuronetics expects net revenue of $37 million to $39 million for Q3 and targets cash flow from operations to be in the range of negative $3 million to breakeven in Q3, turning positive in Q4.
- This is based on the successful optimization of SPRAVATO buy and bill reimbursements and ongoing operational efficiency improvements.
Discover what executives don't want to reveal in conference calls
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet